VERTEX PHARMACEUTICALS INC / MA Business Summary

Vertex Pharmaceuticals Incorporated (VRTX) operates a high-margin biotechnology business model centered on the discovery, development, and commercialization of small-molecule and genetic therapies for life-threatening diseases. The company generates the vast majority of its revenue through product sales, specifically its dominant franchise of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators, including the blockbuster TRIKAFTA/KAFTRIO and the recently launched next-generation triple combination ALYFTREK. As of early 2026, Vertex has successfully diversified its revenue streams into hematology with CASGEVY, the first-ever FDA-approved CRISPR-based gene therapy for sickle cell disease and beta-thalassemia, and into pain management with the commercial rollout of JOURNAVX (suzetrigine), a first-in-class non-opioid analgesic. While Vertex faces emerging pipeline competition in the CF space from firms like 4D Molecular Therapeutics and ReCode Therapeutics, it maintains an unrivaled market position as the global standard-of-care provider, competing broadly against large-cap biopharmaceutical peers such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals. Founded in 1989 by Dr. Joshua Boger, Vertex is currently led by CEO and President Reshma Kewalramani, M.D., FASN, a physician-scientist who succeeded long-time leader Jeffrey Leiden, M.D., Ph.D., in 2020; Dr. Leiden remains active as Executive Chairman. The senior leadership team includes Charles Wagner as EVP and Chief Operating & Financial Officer, Mark Bunnage, D.Phil., as EVP and Chief Scientific Officer, and E. Morrey Atkinson, Ph.D., as EVP and Chief Technical Operations Officer. The company’s strategic direction is supported by a high-pedigree Board of Directors featuring notable figures such as Sangeeta Bhatia, M.D., Ph.D. (MIT professor and biotech pioneer), and Alan Garber, M.D., Ph.D. (President of Harvard University). Vertex remains a favorite of institutional healthcare investors, including the International Biotechnology Trust, due to its robust $11 billion cash position and a late-stage pipeline targeting APOL1-mediated kidney disease and Type 1 diabetes.